Dr. Linda Vahdat on Glembatumumab Vedotin as a Treatment in Triple Negative Breast Cancer

December 29, 2015

Linda Vahdat, MD, discusses the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB.

Linda Vahdat, MD, professor of Medicine, director of the Breast Cancer Research Program, chief of the Solid Tumor Service, Weill Cornell Medical, discusses the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB. Vahdat says the purpose of the drug conjugate is to target gpNMB, also known as osteoactivan, which is important for cell migration and invasion.